Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resme…
Biotechnology
US, West Conshohocken [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 74.72 | 9.39 | 5.38 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 2151.46 | 3.32 | -0.15 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 107.37 | 42.53 | 20.51 | |
| Cash | 65.00 | 52.95 | 32.09 | |
| Capex | 65.96 | -0.02 | -0.05 | |
| Free Cash Flow | -82.43 | -7.48 | -4.10 | |
| Revenue | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.00 | 0.00 | |
| Operating Margin | 0.00 | 0.00 | 0.00 | |
| ROA | 22.17 | -0.14 | -0.18 | |
| ROE | 37.35 | -0.17 | -0.28 | |
| ROIC | 30.08 | -0.16 | -0.22 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of MDGL is permitted for members.
5
Growth
The "Growth Entry" for the Focus of MDGL is permitted for members.
6
Leverage & Liquidity